News

Leyden Labs reports positive Phase 1 results for RIG-101, an investigational intranasal therapy designed to strengthen antiviral defenses and help prevent virus-triggered asthma exacerbations. The results support RIG-101’s advancement into Phase 2 clinical development.

The Leyden Labs team participated in HERA's recent Implementation Dialogue on July 3 in Brussels. In this dialogue, Commissioner Hadja Lahbib actively listened to a set of diverse stakeholders, who can each help prepare …

Spanning Europe, the United States, and Asia, investors include the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others  Ben Verwaayen appointed as a new Supervisory Board member LEIDEN, the Netherlands. June …

In a new paper published in Science Translational Medicine, Leyden Labs reports landmark preclinical and clinical data supporting the development of their antibody-based nasal sprays to prevent influenza infection by neutralizing virus at portal …

On 13 December 2025, Leyden Labs appeared on Dutch national television in Nieuwsuur. During the broadcast, our CEO Koenraad Wiedhaup and TenneT CEO Manon van Beek discussed the crucial role of innovation in strengthening …

Dutch biotech Leyden Labs has raised a €30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray, as well as the Company’s …

The Symposium on the Pandemic Threat of Influenza and Other Respiratory Viruses was held on September 15, 2025 in Singapore, hosted by Duke-NUS Medical School. Leyden Labs was honored to support this event, which …

The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company’s broadly-protective antibodies to defend against seasonal and pandemic …

In vivo influenza protection was achieved at a significantly lower antibody dose with intranasal compared to systemic administration  In contrast to what is observed with systemic administration, Leyden Labs’ lead influenza antibody CR9114 has …

Earlier this week, Jaap Goudsmit, Chief Scientist of Leyden Labs, gave a talk on monoclonal antibodies as preventive tools for H5N1 outbreaks, at the global consultation of the World Health Organization (WHO).

Following exciting advancements with new investments, scientific successes with our Mucosal Protection Platform, and clinical progress in our pipeline, we are happy to announce that we are further strengthening our senior leadership team.

It is an honour for us to announce that Leyden Labs is among the select set of groundbreaking companies awarded funding under EU EIC Accelerator program. Only 71 out of 1211 applications were selected …

Leyden Laboratories B.V. announces it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, …

PanFlu is the recipient of the “Monoclonal Antibody Solution of the Year” award in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough.

CEO Koenraad Wiedhaup recently had the opportunity to share the mission of Leyden Labs with Brad Loncar of Biotech TV during a stop in Leiden on the team’s 2024 European Biotech Tour.

Dr. Ananworanich most recently led influenza vaccine development at Moderna and brings more than 20 years of clinical and industry experience in infectious disease.

The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic.

Leyden Labs CEO Koenraad Wiedhaup will deliver a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024 in San Francisco, CA.

Leyden Laboratories B.V., (the “Company” or “Leyden Labs”) announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114. CR9114 is a universal anti-hemagglutinin stem …

A new article from Leyden Labs has been published in the European Journal of Epidemiology.